Custirsen (OGX-011): Clusterin inhibitor in metastatic prostate cancer

Current Oncology Reports

Volumn 15, Issue 2, 2013, Pages 113-118

  Al Asaaed, Sohaib ^a   Winquist, Eric ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Antisense oligonucleotides; Clusterin; Custirsen; Prostate cancer; Resistance

Indexed keywords

ABIRATERONE ACETATE; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CABAZITAXEL; CLUSTERIN; CUSTIRSEN; CYTOTOXIC AGENT; DOCETAXEL; ENZALUTAMIDE; MITOXANTRONE; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PROTEIN P53; RADIOPHARMACEUTICAL AGENT; RADIUM 223; RIBONUCLEASE H; UNCLASSIFIED DRUG;

ANDROGEN DEPRIVATION THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE METASTASIS; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CASTRATION SENSITIVE PROSTATE CANCER; CHILL; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FEVER; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG TARGETING; DRUG TISSUE LEVEL; DRUG TUMOR LEVEL; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; LYMPH NODE METASTASIS; MAXIMUM PLASMA CONCENTRATION; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHUMAN; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; RECOMMENDED DRUG DOSE; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; CLUSTERIN; HUMANS; MALE; PROSTATIC NEOPLASMS; THIONUCLEOTIDES;

EID: 84879445695     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-012-0285-1     Document Type: Article

References (56)

1. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al. International variation in prostate cancer incidence and mortality rates. European Urol. 2012;61(6):1079-92.
2. Di Lorenzo G, Buonerba C, Autorino R, De Placido S, Sternberg CN. Castration-resistant prostate cancer: current and emerging treatment strategies. Drugs. 2010;70(8):983-1000.
3. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010;19(8):1893-907.
4. Gleave M, Miyake H, Chi K. Beyond simple castration: targeting the molecular basis of treatment resistance in advanced prostate cancer. Cancer Chemother Pharmacol. 2005;56:47-57.
5. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14(6):1756-64.
6. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502-12.
7. Petrylak DP, Tangen CM, Hussain MH, Lara Jr PN, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513-20.
8. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels J-P, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147-54.
9. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995-2005.
10. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187-97.
11. Parker C, Heinrich D, O'Sullivan JM, Fossa SD, Chodacki A, Demkow T, et al. Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: Results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases. J Clin Oncol 30, 2012 (suppl 5; abstr 8).
12. Galletti E, Magnani M, Renzulli ML, Botta M. Paclitaxel and docetaxel resistance: molecular mechanisms and development of new generation taxanes. Chem Med Chem. 2007;2(7):920-42.
13. Seruga B, Tannock IF. Chemotherapy-based treatment for castration-resistant prostate cancer. J Clin Oncol. 2011;29(27):3686-94.
14. Cortes JE, Pazdur R. Docetaxel. J Clin Oncol. 1995;13(10):2643-55.
15. Sissung TM, Baum CE, Deeken J, Price DK, Aragon-Ching J, Steinberg SM, et al. ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel. Clin Cancer Res. 2008;14(14):4543-9.
16. Bouchet BP, Galmarini CM. Cabazitaxel, a new taxane with favorable properties. Drugs Today (Barc). 2010;46(10):735-42.
17. Zoubeidi A, Chi K, Gleave M. Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer. Clinical Cancer Res. 2010;16(4):1088-93.
18. Miyake H, Nelson C, Rennie PS, Gleave ME. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models. Cancer Res. 2000;60(9):2547-54.
19. Miyake H, Hara I, Gleave ME, Eto H. Protection of androgen-dependent human prostate cancer cells from oxidative stress-induced DNA damage by overexpression of clusterin and its modulation by androgen. Prostate. 2004;61(4):318-23.
20. Yamanaka K, Rocchi P, Miyake H, Fazli L, So A, Zangemeister-Wittke UWE, et al. Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl-2 and Bcl-xL genes. BJU Int. 2006;97(6):1300-8.
21. Gleave ME, Miyake H, Zellweger T, Chi K, July L, Nelson C, et al. Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer. Urology. 2001;58(2, Suppl 1):39-48.
22. Rizzi F, Bettuzzi S. The clusterin paradigm in prostate and breast carcinogenesis. Endocr Relat Cancer. 2010;17(1):R1-R17.
23. Shannan B, Seifert M, Leskov K, Willis J, Boothman D, Tilgen W, et al. Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer. Cell Death Differ. 2006;13(1):12-9.
24. Calero M, Rostagno A, Matsubara E, Zlokovic B, Frangione B, Ghiso J. Apolipoprotein J (clusterin) and Alzheimer's disease. Microsc Res Tech. 2000;50(4):305-15.
25. Rosenberg ME, Silkensen J. Clusterin and the kidney. Exp Nephrol. 1995;3(1):9-14.
26. Rizzi F, Bettuzzi S. Targeting clusterin in prostate cancer. J Physiol Pharmacol. 2008;59 Suppl 9:265-74.
27. Rizzi F, Caccamo AE, Belloni L, Bettuzzi S. Clusterin is a short half-life, poly-ubiquitinated protein, which controls the fate of prostate cancer cells. J Cell Phys. 2009;219(2):314-23.
28. Pucci S, Bonanno E, Pichiorri F, Angeloni C, Spagnoli LG. Modulation of different clusterin isoforms in human colon tumorigenesis. Oncogene. 2004;23(13):2298-304.
29. Zhang Q, Zhou WEI, Kundu S, Jang TL, Yang X, Pins M, et al. The leader sequence triggers and enhances several functions of clusterin and is instrumental in the progression of human prostate cancer in vivo and in vitro. BJU Int. 2006;98(2):452-60.
30. Zhang H, Kim JK, Edwards CA, Xu Z, Taichman R, Wang C-Y. Clusterin inhibits apoptosis by interacting with activated Bax. Nat Cell Biol. 2005;7(9):909-15.
31. Bettuzzi S, Davalli P, Davoli S, Chayka O, Rizzi F, Belloni L, et al. Genetic inactivation of apoJ/clusterin: effects on prostate tumourigenesis and metastatic spread. Oncogene. 2009;28(49):4344-52.
32. Zellweger T, Kiyama S, Chi K, Miyake H, Adomat H, Skov K, et al. Overexpression of the cytoprotective protein clusterin decreases radiosensitivity in the human LNCaP prostate tumour model. BJU Int. 2003;92(4):463-9.
33. Steinberg J, Oyasu R, Lang S, Sintich S, Rademaker A, Lee C, et al. Intracellular levels of SGP-2 (clusterin) correlate with tumor grade in prostate cancer. Clin Cancer Res. 1997;3(10):1707-11.
34. July LV, Akbari M, Zellweger T, Jones EC, Goldenberg SL, Gleave ME. Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate. 2002;50(3):179-88.
35. Gleave ME, Zellweger T, Chi K, Miyake H, Kiyama S, July L, et al. Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- and chemo-sensitivity in prostate cancer. Invest New Drugs. 2002;20(2):145-58.
36. Crooke ST. Progress in antisense technology. Annu Rev Med. 2004;55:61-95.
37. Crooke ST. Molecular mechanisms of action of antisense drugs. Biochim Biophys Acta. 1999;1489(1):31-44.
38. Chi KN, Gleave ME. Antisense approaches in prostate cancer. Expert Opin Biol Ther. 2004;4(6):927-36.
39. Gleave M, Miyake H, Zangemeister-Wittke U, Jansen B. Antisense therapy: current status in prostate cancer and other malignancies. Cancer Metastasis Rev. 2002;21(1):79-92.
40. Miyake H, Hara I, Gleave ME. Antisense oligodeoxynucleotide therapy targeting clusterin gene for prostate cancer: Vancouver experience from discovery to clinic. Int J Urol. 2005;12(9):785-94.
41. Zellweger T, Miyake H, Cooper S, Chi K, Conklin BS, Monia BP, et al. Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2'-O-(2-methoxy)ethyl chemistry. J Pharmacol Exp Ther. 2001;298(3):934-40.
42. Miyake H, Nelson C, Rennie PS, Gleave ME. Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. Cancer Res. 2000;60(1):170-6.
43. Miyake H, Tolcher A, Gleave ME. Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model. Cancer Res. 1999;59(16):4030-4.
44. Sowery RD, Hadaschik BA, So AI, Zoubeidi A, Fazli L, Hurtado-Coll A, et al. Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy. BJU Int. 2008;102(3):389-97.
45. Zellweger T, Chi K, Miyake H, Adomat H, Kiyama S, Skov K, et al. Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin. Clin Cancer Res. 2002;8(10):3276-84.
46. •• Chi KN, Eisenhauer E, Fazli L, Jones EC, Goldenberg SL, Powers J, et al. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst. 2005;97(17):1287-96. This is an elegant translational proof-of-principle study demonstrating efficacy of custirsen in human prostate cancer in vivo.
47. Chi KN, Siu LL, Hirte H, Hotte SJ, Knox J, Kollmansberger C, et al. A phase I study of OGX-011, a 2'-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. Clin Cancer Res. 2008;14(3):833-9.
48. • Chi KN, Hotte SJ, Yu EY, Tu D, Eigl BJ, Tannock I, et al. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2010;28(27):4247-54. There was improved overall survival with addition of custirsen therapy to docetaxel therapy in this randomized phase II trial.
49. Saad F, Hotte S, North S, Eigl B, Chi K, Czaykowski P, et al. Randomized phase II trial of custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG Trial P-06c. Clin Cancer Res. 2011;17(17):5765-73.
50. A phase II study of OGX-011 given prior to radical prostatectomy in patients with localized prostate cancer (NCT00138918). ClinicalTrials.gov. Accessed 15 Nov 2012.
51. Comparison of docetaxel/prednisone to docetaxel/prednisone in combination with OGX-011 in men with prostate cancer (SYNERGY) (NCT01188187). ClinicalTrials.gov. Accessed 15 Nov 2012.
52. Comparison of cabazitaxel/prednisone alone or in combination with custirsen for 2nd line chemotherapy in prostate cancer (AFFINITY) (NCT01578655). ClinicalTrials.gov. Accessed 15 Nov 2012.
53. A study evaluating the pain palliation benefit of adding custirsen to docetaxel retreatment or cabazitaxel as second line therapy in men with metastatic castrate resistant prostate cancer (mCRPC) (NCT01083615). ClinicalTrials.gov. Accessed 15 Nov 2012.
54. OGX-011 and docetaxel in treating women with locally advanced or metastatic breast cancer (NCT00258375). ClinicalTrials.gov. Accessed 15 Nov 2012.
55. A study of OGX-011/gemcitabine/platinum-based regimen in stage IIIB/IV non-small cell lung cancer (NSCLC) (NCT00138658). ClinicalTrials.gov. Accessed 15 Nov 2012.
56. A multinational, randomized, open-label study of custirsen in patients with advanced or metastatic (stage IV) non-small cell lung cancer (NCT01630733). ClinicalTrials.gov. Accessed 15 Nov 2012.